Please login to the form below
Ionis
This page shows the latest Ionis news and features for those working in and with pharma, biotech and healthcare.
GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2
GlaxoSmithKline has announced positive results from a phase 2a study of its Ionis-partnered antisense medicine for chronic hepatitis B virus (CHB) infection. ... As part of the licensing deal, Ionis is set to receive fees and milestone payments of up to
Latest news
-
Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy
In the ATTR polyneuropathy indication it has competition from Alnylam’s injectable drugs Onpattro (patisiran) and Ionis’ Tegsedi (inotersen), which were approved for that use in Europe in 2018.
-
Merck strengthens KRAS stake with Taiho and Astex partnership
Other competitors in the KRAS inhibitor race include Mirati, Boehringer Ingelheim, Johnson &Johnson/Wellspring and AstraZeneca/Ionis.
-
Biogen bets on Ionis’ early-stage Alzheimer’s drug
payout. . The drug – IONIS-MAPTRx – is an antisense therapy designed to reduce production of microtubule-associated protein tau (MAPT) or tau in the central nervous system. ... In pre-clinical research, IONIS-MAPTRx demonstrated prevention of
-
Pfizer pays $250m upfront to Akcea for phase 2 antisense drug
Has potential in cardiovascular and metabolic diseases. Pfizer has bolted on an antisense drug with potential in cardiovascular and metabolic diseases to its pipeline via a licensing deal with Ionis’ Akcea ... Founded in 2015, Akcea spun out of Ionis
-
Biogen’s R&D chief Ehlers heads for the exit
There’s still plenty in the neuroscience pipeline however, including tofersen for amyotrophic lateral sclerosis (ALS) which stems from an alliance with antisense specialist Ionis and is due for a phase
More from news
Approximately 17 fully matching, plus 32 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
Standing in its way is a similarly priced antisense rival from Ionis and Akcea – Tegsedi (inotersen) – as well as Pfizer’s fast- growing Vyndaqel/Vyndamax (tafamidis), which is approved for hATTR
-
Where next in Alzheimer’s disease R&D?
The big biotech is testing its own BIIB092 in early Alzheimer’s patients and has an option to develop an Ionis Pharmaceuticals’ antisense drug designed to reduce production of tau in
-
Deal Watch October 2018
Joint development using SQZ’s cell therapy. platform. $1.375B. Option. Ionis. RNA‐targeted therapeutics for complement mediated. ... RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
While Onpattro has outshone Ionis’ product in safety and efficacy, analysts see Onpattro’s lack of cardiovascular claims in its US label as a weak point. ... England’s NICE is just beginning its review of Onpattro (in tandem with a review of
-
The European Medicines Agency: PRIME’d for access?
Since March 2018 Roche, with Ionis, have added another PRIME drug to their portfolio. ... RG6042 (formerly named IONIS-HTTRx) is in development for Huntington’s disease.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- New medical communications agency BOLDSCIENCE launches
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- 20 for 2020 – Five pharma companies to watch
- FDA approves Roche’s Actemra COVID-19 trial
- Shionogi's Gram-negative antibiotic launches in the UK
- The flexible salesforce
- Navigating engagement and remote working during the pandemic
- Improve clinical trials through patient journey mapping
- Live Webinar: Medical Modeling in Virtual Reality
- Live Webinar: Telemedicine & the Digitization of Medicine post COVID-19
- Havas Health & You Launches Behind the Mask, a Global Research Initiative to Document Health Experiences During the COVID-19 Pandemic and Beyond
PMHub
11 London
11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...
Latest intelligence
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
Quick links
Infographics
